Results of the prognostic factor analysis of patients from the anlotinib group (univariate analysis)

Item	PFS		OS
Item	P	HR (95%CI)	P	HR (95%CI)
Age	0.003	0.639 (0.478, 0.856)	0.456	1.126 (0.824, 1.538)
Post-treatment ECOG	0.445	1.164 (0.789, 1.717)	< 0.001	2.219 (1.489, 3.836)
Post-treatment granulocytes/lymphocytes	< 0.001	2.013 (1.405, 2.548)	< 0.001	2.651 (1.884, 3.732)
Pre-randomization maximal target lesion length	0.360	1.144 (0.857, 1.528)	< 0.001	2.049 (1.498, 2.803)
Hypertension	< 0.001	0.466 (0.341, 0.637)	0.004	0.617 (0.445, 0.854)
Hand-foot syndrome	< 0.001	0.476 (0.354, 0.640)	< 0.001	0.483 (0.348, 0.669)
Oral mucositis	0.031	0.693 (0.497, 0.967)	0.051	0.691 (0.476, 1.001)
Prolonged QT interval in ECG	0.010	0.646 (0.463, 0.900)	0.741	0.942 (0.662, 1.341)
Hyperglycemia	0.007	0.662 (0.491, 0.892)	0.735	1.059 (0.759, 1.477)
Hypertriglyceridemia	< 0.001	0.453 (0.329, 0.623)	< 0.001	0.462 (0.335, 0.639)
Hypercholesterolemia	0.001	0.558 (0.392, 0.794)	0.004	0.629 (0.540, 1.173)
Hyper-low density lipoproteinemia	0.001	0.502 (0.330, 0.762)	0.321	0.830 (0.516, 1.320)
Elevated thyroid stimulating hormone	0.001	0.591 (0.434, 0.805)	0.004	0.620 (0.449, 0.857)
Elevated alkaline phosphatase	0.008	1.519 (1.118, 2.065)	0.005	1.609 (1.159, 2.234)
Hypocalcemia	0.314	1.303 (0.778, 2.184)	0.012	1.876 (1.146, 3.071)
Hyponatremia	0.092	1.337 (0.954, 1.875)	0.001	1.971 (1.390, 2.795)
Hypomagnesemia	0.026	0.485 (0.256, 0.918)	0.468	0.789 (0.416, 1.497)